Are We Missing the Genetic Risk of Womb Cancer?

Synopsis
A recent study highlights alarming gaps in the testing for Lynch syndrome among womb cancer patients, putting them and their families at greater risk. With only a fraction tested and many unaware, urgent action is needed to address this critical health issue.
Key Takeaways
- Lynch syndrome significantly increases cancer risk.
- Only 5% of affected individuals are aware of their condition.
- Timely referrals for genetic counseling are often lacking.
- Only 48% of eligible patients receive follow-up testing.
- Early detection can lead to preventive treatments.
New Delhi, June 11 (NationPress) A recent study reveals that patients diagnosed with womb or uterine cancer are not undergoing testing for a genetic condition that significantly elevates their risk of developing additional cancers.
Lynch syndrome is a hereditary condition that predisposes individuals to womb and bowel cancer. Although it affects approximately one in 300 people, only five percent are aware of their status.
Researchers from the University of Edinburgh emphasized that identifying Lynch syndrome is critical, as it allows patients to take proactive measures to mitigate their cancer risk. This not only enhances patient outcomes but also decreases healthcare expenditures.
The study, published in the journal BMJ Oncology, analyzed over 2,500 womb cancer cases in the UK and Ireland from 2022 to 2023.
While 91 percent of tumors were screened for Lynch syndrome markers, the results were not consistently shared with the broader clinical team, leading to a lack of follow-up genetic counseling and blood tests.
Of those eligible for genetic counseling, only two-thirds were actually referred for appointments.
Patients who were referred encountered prolonged waiting periods, resulting in significant drop-out rates. The study indicated that only 48 percent of womb cancer patients who required further testing ultimately received a blood test.
These testing gaps mean that many womb cancer patients with Lynch syndrome remain undiagnosed, putting them at risk for bowel cancer. Family members are also left exposed to potential cancer risks, unaware that they might have the condition.
“Despite clear guidelines and commendable tumor testing rates, far too many women with Lynch syndrome are overlooked due to delays in referrals for definitive blood tests. This not only denies them the opportunity to decrease their future cancer risk but also hinders their relatives from being tested and safeguarded,” said Dr. Neil Ryan, a clinical lecturer at the University of Edinburgh’s Centre for Reproductive Health.
“Tumor testing is only cost-effective if it leads to diagnosis -- we urgently need to make mainstream testing truly mainstream,” he added.
Identifying cases early would allow for the implementation of preventive strategies to lower the risk of subsequent cancers, such as taking aspirin and undergoing regular colonoscopies to prevent bowel cancer, or hysterectomies to avert womb cancer, as stated by the researchers.